-+ 0.00%
-+ 0.00%
-+ 0.00%

IDEAYA Biosciences Names IDE101 Development Candidate for CDKN2A-Deficient Solid Tumors

PUBT·11/15/2026 20:00:29
Listen to the news
IDEAYA Biosciences Names IDE101 Development Candidate for CDKN2A-Deficient Solid Tumors
  • IDEAYA Biosciences nominated IDE101 as a development candidate targeting CDKN2A-deficient solid tumors, with an FDA investigational new drug filing planned for first-half 2027.
  • Preclinical studies showed encouraging activity alone and with RAS or PRMT5 inhibitors, including IDE892, supporting planned combination development.
  • Results, including PRMT5 and pan-RAS combination findings, will be presented at the company's London R&D Day.
  • CDKN2A deficiency occurs in approximately 10-15% of solid tumors, including about 70% of pancreatic ductal adenocarcinomas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151500PR_NEWS_USPR_____SF97781) on November 15, 2026, and is solely responsible for the information contained therein.